Tade, F. I.
Wiles, W. G. IV
Lu, G.
Bilir, B.
Akin-Akintayo, O.
Lee, J. S.
Patil, D.
Yu, W.
Ormenisan Gherasim, C.
Fei, B.
Moreno, C. S.
Osunkoya, A. O.
Teoh, E. J.
Oka, S.
Okudaira, H.
Goodman, M. M.
Schuster, D. M.
Funding for this research was provided by:
Winship Cancer Institute (P30 CA138292)
Article History
Received: 24 November 2017
Accepted: 5 June 2018
First Online: 15 June 2018
Compliance with ethical standards
:
: Emory University licensed and approved the 18F-fluciclovine patent technology in accordance with the Emory Conflict of Interest Committee policies. M. M. Goodman and Emory University are eligible to receive royalties derived from the sale of 18F-fluciclovine. H. Okudaira and S. Oka are employees of Nihon Medi-Physics Co., Ltd. (NMP) and collaborate with M. M. Goodman and D. M. Schuster on preclinical and clinical studies involving 18F-fluciclovine. F. I. Tade, O. Akin-Akintayo, and D. M. Schuster receive funding/resources from Blue Earth Diagnostics Ltd. and Nihon Medi-Physics Co., Ltd. through the Emory University Office of Sponsored Projects for research outside that reported in this manuscript. All other co-authors declared no conflicts of interest.
: This study was performed with the approval of the Institutional Animal Care and Use Committee. All procedures performed in this study using animals were in accordance with institutional and/or national guidelines and ethical standards for the care and use of animals. No human studies were conducted.
: No human studies were conducted.